Observational Analysis of the Costs Associated with Acute Treatment of Breakthrough Migraine Attacks in Medicaid Patients Using Preventive Therapies.

导出 OA

翻译打印收藏纠错

第一作者： Linda,Harris

第一单位： Biohaven Pharmaceuticals, New Haven, CT, USA.

作者： Linda,Harris ^[1] ; Tom,O'Connell ^[2] ; Jonathan J,Woolley ^[3] ; Gilbert,L'Italien ^[4] ; Tamela,Martin ^[1] ; Vladimir,Coric ^[1] ; James A,Moren ^[1]

作者单位： Biohaven Pharmaceuticals, New Haven, CT, USA. ^[1] Medicus Economics, Boston, MA, USA. thomas.oconnell@gmail.com. ^[2] , 723 47th Ave, San Francisco, CA, 94121, USA. thomas.oconnell@gmail.com. ^[3] Medicus Economics, Boston, MA, USA. ^[4] American Headache Society, Mount Royal, NJ, USA. ^[5]

关键词 Breakthrough Cost Dihydroergotamine Intranasal Medicaid Migraine, acute Migraine, prevention Monoclonal antibody Monthly migraine day Triptan

主题词人类(Humans);双氢麦角胺(Dihydroergotamine);降钙素基因相关肽(Calcitonin Gene-Related Peptide);Medicaid(Medicaid);偏头痛(Migraine Disorders);抗体, 单克隆(Antibodies, Monoclonal);色胺类(Tryptamines)

DOI 10.1007/s12325-022-02386-w

PMID 36648736

发布时间 2023-03-26

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交